Imago BioSciences Q2 EPS $(8.13) Down From $(3.66) YoY

Imago BioSciences (NASDAQ:IMGO) reported quarterly losses of $(8.13) per share. This is a 122.13 percent decrease over losses of $(3.66) per share from the same period last year.

byBenzinga Newsdesk

August 19, 2021

1 minute read

Imago BioSciences (NASDAQ:IMGO) reported quarterly losses of $(8.13) per share. This is a 122.13 percent decrease over losses of $(3.66) per share from the same period last year.

Earnings

Earnings Outlook For Crown Holdings

By Benzinga Insights

Today, 10:36 PM

Crown Holdings (NYSE:CCK) will be releasing its next round of earnings this Monday, July 19. For all of the relevant information, here is your guide for Monday's Q2 earnings announcement.

CCK

Earnings

Earnings Outlook For Advanced Drainage Systems

By Benzinga Insights

Today, 10:36 PM

Advanced Drainage Systems (NYSE:WMS) is set to give its latest quarterly earnings report on Thursday, 2022-05-19. Here's what investors need to know before the announcement. Analysts estimate that Advanced Drainage Systems will report an earnings per share (EPS) of $0.66.

WMS

Goldman Sachs Maintains Neutral on Vacasa, Lowers Price Target to $4

By Benzinga Newsdesk

Today, 10:36 PM

Goldman Sachs analyst Eric Sheridan maintains Vacasa (NASDAQ:VCSA) with a Neutral and lowers the price target from $6 to $4.

VCSA

High-Yield Savings Rate At Goldman Sachs Back To Pre-COVID-19 Pandemic Levels: What It Means For Consumers

By AJ Fabino

Today, 10:36 PM

Some banks are starting to raise returns on high-interest savings accounts to pre-COVID-19 pandemic levels as stocks have recovered after inflation appeared to moderate slightly in August — to 8.5% — amid four straight increases in interest rates by the Federal Reserve.

ALLY

Imago BioSciences Q2 EPS $(8.13) Down From $(3.66) YoY

Related Posts

Earnings Outlook For Crown Holdings

Earnings Outlook For Advanced Drainage Systems

Goldman Sachs Maintains Neutral on Vacasa, Lowers Price Target to $4

High-Yield Savings Rate At Goldman Sachs Back To Pre-COVID-19 Pandemic Levels: What It Means For Consumers